Benchmark lowered the firm’s price target on Humacyte to $15 from $16 and keeps a Buy rating on the shares. The firm is updating its models to reflect a new share count assumption, noting that earlier this month the company submitted a Biologics License Application to the FDA for approval of its Human Acellular Vessel in urgent arterial repair and has requested Priority Review of the application.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HUMA:
- 2 Best Stocks to Buy Now, 13/12/2023, According to Top Analysts
- Humacyte submits BLA to U.S. FDA seeking approval of HAV
- Humacyte initiated with bullish view at H.C. Wainwright, here’s why
- Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
- Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
